LifeStance Health Reports Patient Symptom Improvements Following Esketamine and TMS Treatments

LifeStance Health has released outcomes data showing meaningful reductions in depression symptoms and suicidal ideation among patients receiving specialty treatments for treatment-resistant depression. According to the company's published analyses, patients treated with esketamine (Spravato) or transcranial magnetic stimulation (TMS) demonstrated symptom improvements evaluated via the Patient Health Questionnaire (PHQ-9).

Treatment-resistant depression affects individuals who experience persistent depressive symptoms despite conventional antidepressant medications or psychotherapies. LifeStance's analyses evaluated observational results for patients receiving these specific specialty care options.

Key Findings from LifeStance Analyses

• Esketamine Outcomes: Among 258 evaluated patients, 74% experienced a clinically meaningful reduction in depression severity after 12 weeks of treatment. Daily suicidal ideation dropped from 13% before treatment to 2% following treatment.
• TMS Outcomes: Among 355 evaluated patients, 61% experienced a clinically meaningful reduction in depression severity after completing at least 30 treatment sessions. Daily suicidal ideation dropped from 13% before treatment to 6% following treatment.

Dr. Stephanie Eken, Chief Medical Officer at LifeStance Health, noted that these options offer new hope for patients who have struggled to find relief through traditional means.

Practical Implications and Verification

These observational results describe specific patient cohorts and do not guarantee individual outcomes. The full outcomes reports can be reviewed on the official LifeStance website.

*If you or someone you know is in crisis, support is available. You can call, text, or chat with the Suicide and Crisis Lifeline at 988, or text TALK to 741741 to reach the Crisis Text Line.